Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 46

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 46
---
 if we are unable to successfully
integrate them with our existing operations and company culture. For instance, certain of our agreements may require significant R&D
that may not result in the development and commercialization of product candidates. We cannot be certain that, following a strategic
transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction.

We will need substantial additional financing to develop our product candidates and implement our operating plans, which financing we may be unable to obtain, or unable to obtain on acceptable terms. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.

We expect to spend a substantial
amount of capital in the development and manufacturing of our product candidates, and we will need substantial additional financing to
do so. In particular, we will require substantial additional financing to enable commercial production of our product candidates and
initiate and complete registrational trials for multiple products in multiple regions. Further, if approved, we will require significant
additional capital in order to launch and commercialize our product candidates.

As of September 30, 2024,
we had approximately $3.3 million in cash and cash equivalents. Changing circumstances may cause us to consume capital significantly
faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our
control. We may also need to raise additional capital sooner than we currently anticipate if we choose to expand more rapidly than we
presently plan. In any event, we will require additional capital for the further development and commercialization of our product candidates,
including funding our internal manufacturing capabilities.

We cannot be certain that
additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital. If we are unable
to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue
the development or commercialization of our product candidates or other R&D initiatives. We could be required to seek collaborators
for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise
be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek
to pursue development or commercialization ourselves.

Any of the above events
could significantly harm our business, prospects, financial condition and results of operations and cause the price of our Common Stock
to decline.

Raising additional capital